Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US. The open-label Phase 2/3 uveal melanoma trial tested the ...
Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial
